Shareholder Update: December 2011
In this issue:
› Starpharma raises $35m to advance pipeline
› Starpharma signs with Ansell for condom coating
› Putting a stop to stubborn BV: The VivaGel© solution
› Clinical trials for VivaGel© gather pace
› M&G invests $20 million
› Dendrimers through the eyes of Professor Donald Tomalia
Download: Shareholder Update: December 2011 (pdf file, 628kb)
Starpharma's drug delivery program with Lilly advances
Starpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.
Starpharma SPP closes heavily oversubscribed; completing $35m financing
Starpharma today announced that its Share Purchase Plan (SPP) which closed on Wednesday 7 December 2011, is oversubscribed by more than 400%. The SPP was capped at $3 million, and shareholders have subscribed a total in excess of $12 million.
Herald Sun: Small fry happy to follow the right moves
Herald Sun Journalist John Beveridge takes a close look at why M&G made a significant investment in Starpharma and what it could mean for other buyers: ‘If you see a clever investor grabbing a stake in a company, there is no problem piggy-backing on their research and following them on board.’
Go to the article (external link)